Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis

The Toll-like-receptor 9 (TLR-9) agonist cobitolimod (DIMS0150, Kappaproct ®) is a promising therapeutic option for ulcerative colitis (UC) patients.

Source: Digestive and Liver Disease - June 22, 2018 Category: Gastroenterology Authors: Raja Atreya, Walter Reinisch, Laurent Peyrin-Biroulet, Franco Scaldaferri, Charlotte Admyre, Thomas Knittel, Jan Kowalski, Markus Friedrich Neurath, Christopher Hawkey Tags: Alimentary Tract Source Type: research